Mercado's innovative antibiotic combination Recarbrio is approved by fda

today, the U.SFDA(http://approved the listing of Recarbrio, an innovative antibiotic combination developed by the
of Mshttp://to treat complex urinary tract infections (cUTI) and complex intra-abdominal infections (cIAI) caused by specific sensitive Gram-negative bacteriaIn antibiotics, we are known for penicillin and cephalosporins, which are beta-lactam antibiotics, but the long-term use of these antibiotics also allows bacteria to develop resistance to them through a variety of mechanismsIn gram-negative bacteria, the main mechanism for resistance to beta-lactamantibiotics is beta-lactamase, which destroys the endamide ring in these antibiotics, thereby inactive theof(http:// ofdrugsOne way to overcome this bacterial resistance is to develop a new generation of beta-lactam antibiotics that will enable them to resist the effects of beta-lactamase, or to develop inhibitors that inhibit the activity of beta-lactamaseAlthough beta-lactamase inhibitors themselves are not antibiotic-active, they can increase the activity of beta-lactam antibioticsAbout Recarbio
Recarbio is an antibacterial product (http:// made up of relebactam, imipenem and cilastatin, an innovative beta-lactamase inhibitor, an approved beta-lactamide antibiotic, and cilastinin prevents imipenem from being broken down by the kidneys 　　Relebactam, developed by Mercado, is a Class A and C beta-lactamase inhibitor that is administered intravenously 　　The combination of Relevantam and imipenem and cilastatin has been eligible for FDA-awarded Qualified Infectious Disease Products (QIDP) and fast-track eligibility for the treatment of cUTI, cIAI, and hospital-acquired bacterial pneumonia/respirator-related bacterial pneumonia (HABP/VABP) 　　This approval is based on the efficacy and safety results of the imipenem-cilastatin combination therapy cUTI and cIAI, as well as the findings of relebactam in in vitro studies and animal infection models 　　The safety of Recarbrio is demonstrated in two clinical trials (http:// treating patients with cUTI and cIAI